Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

PURPOSE: There are no known effective medical treatments for refractory MPNST. Inactivation of the NF1 tumor suppressor in MPNST results in upregulation of mTOR (mammalian target of rapamycin) signaling and angiogenesis, which contributes to disease progression. We conducted a phase II study for pat...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Sarcoma
Главные авторы: Widemann, Brigitte C., Lu, Yao, Reinke, Denise, Okuno, Scott H., Meyer, Christian F., Cote, Gregory M., Chugh, Rashmi, Milhem, Mohammed M., Hirbe, Angela C., Kim, AeRang, Turpin, Brian, Pressey, Joseph G., Dombi, Eva, Jayaprakash, Nalini, Helman, Lee J., Onwudiwe, Ndidi, Cichowski, Karen, Perentesis, John P.
Формат: Artigo
Язык:Inglês
Опубликовано: Hindawi 2019
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6681622/
https://ncbi.nlm.nih.gov/pubmed/31427883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/7656747
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы